Lipitor, Atorvastatin
Lipitor, Atorvastatin Newswire (Page 5)

Lipitor, Atorvastatin Newswire (Page 5)

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic). (Page 5)

Results 81 - 100 of 799 in Lipitor, Atorvastatin (generic)

  1. Billion-dollar babiesRead the original story w/Photo

    Nov 26, 2015 | The Economist

    The high cost of R&D is used to explain why drugs giants merge, and why they must charge high prices. The reality is somewhat different AS THEY announced the proposed merger of Pfizer and Allergan to create the world's biggest drugmaker, on November 23rd, the two firms' bosses stressed the scale that is needed to keep inventing blockbuster treatments.

    Comment?

  2. Novo Nordisk's First Diabetes Pill Could Be A $10-20 Billion Super-BlockbusterRead the original story w/Photo

    Nov 25, 2015 | Seeking Alpha

    In the drug business, pharmaceutical blockbusters are those that exceed $1B in sales per year. There is a special term for a drug that exceeds $10B in sales: super-blockbuster.

    Comment?

  3. Novo Nordisk's First Diabetes Pill Could Be A $10-20B Super-BlockbusterRead the original story w/Photo

    Nov 25, 2015 | Seeking Alpha

    In the drug business, pharmaceutical blockbusters are those that exceed $1B in sales per year. There is a special term for a drug that exceeds $10B in sales: super-blockbuster.

    Comment?

  4. $160 billion Pfizer, Allergan deals forms world's largest drugmakerRead the original story w/Photo

    Nov 24, 2015 | The Day

    Pfizer and Allergan are joining in the biggest buyout of the year, a $160 billion stock deal that will create the world's largest drugmaker. It's also the largest so-called inversion, where an American corporation combines with a company headquartered in a country with a lower corporate tax rate, saving potentially millions each year in U.S. taxes.

    Comment?

  5. Pfizer, Allergan DealRead the original story w/Photo

    Nov 24, 2015 | Lowell Sun

    Pfizer and Allergan are joining in the biggest buyout of the year, a $160 billion stock deal that will create the world's largest drugmaker. It's also the largest so-called inversion, where an American corporation combines with a company headquartered in a country with a lower corporate tax rate, saving potentially millions each year in U.S. taxes.

    Comment?

  6. Pfizer, Allergan to merge in $160 billion inversionRead the original story

    Nov 23, 2015 | Columbia Daily Herald

    Pfizer and Allergan on Monday morning announced they would merge in a massive, $160 billion deal that will create the world's largest drugmaker, producing treatments as varied as Lipitor and Botox. The deal is structured as a reverse-merger, with smaller Dublin-based Allergan buying U.S.-based Pfizer, and it is likely to renew concerns over "inversions," where U.S. companies are bought by or merge with foreign firms in order to reduce U.S. corporate tax burdens.

    Comment?

  7. Pfizer, Allergan reach US$160B deal to create a pharmaceutical giantRead the original story w/Photo

    Nov 23, 2015 | CTV

    Pfizer and Allergan are joining in the biggest buyout of the year, a US$160-billion stock deal that will create the world's largest drugmaker. It's also the largest so-called inversion, where an American corporation combines with a company headquartered in a country with a lower corporate tax rate, saving potentially millions each year in U.S. taxes.

    Comment?

  8. Smith: Former Angel Rod Carew grateful to be alive after September heart attackRead the original story w/Photo

    Nov 23, 2015 | The Press-Enterprise

    The Baseball Hall of Famer's voice was soft and slow, trailing off near the end of sentences so he could take another labored breath. Rod Carew, the former Angel and beloved 18-time All-Star, was tired and weak on Monday, still recovering after suffering a massive heart attack on Sept.

    Comment?

  9. Drug giant Pfizer aims to buy Botox-maker Allergan in $160bn dealRead the original story w/Photo

    Nov 23, 2015 | Cosmetics Design

    US pharmaceuticals player Pfizer has agreed to buy Botox-maker Allergan for an estimated $160bn in a deal that will create the largest drug-maker in the world. Both companies also have a number of activities in the cosmetics and personal care world.

    Comment?

  10. Viagra maker Pfizer and Botox maker Allergan ink US$160 billion dealRead the original story w/Photo

    Nov 23, 2015 | Stuff.co.nz

    Viagra maker Pfizer is buying Botox maker Allergan in a record-breaking deal worth US$160 billion , designed to cut the company's US tax bill by moving its headquarters to Ireland. The companies' combined medicine chest would put Pfizer staples such as impotence treatment Viagra, cholesterol fighter Lipitor and nerve pain treatment Lyrica alongside Allergan's Botox wrinkle treatment, Alzheimer's drug Namenda and dry-eye medication Restasis.

    Comment?

  11. $160B Pfizer, Allergan merger raises outcryRead the original story w/Photo

    Nov 23, 2015 | Contra Costa Times

    A $160 billion deal announced Monday to merge Pfizer and Allergan and create the world's biggest drug company renewed the outcry in Washington over "inversions," in which U.S. corporations combine with companies overseas to lower their tax bill. The combination -- the second-largest merger in history -- could have ramifications around the globe, pushing up drug prices and spurring more such deals in the fast-consolidating health care sector and other fields.

    Comment?

  12. Pfizer, Allergan Merge to Form World's Largest DrugmakerRead the original story w/Photo

    Nov 23, 2015 | Chosun Ilbo

    Two large drugmakers, U.S.-based Pfizer and Ireland's Allergan, joined forces Monday, creating the world's biggest drug manufacturer. The $160-billion stock deal will push the combined companies, to be called Pfizer Plc and based in Ireland, past Switzerland's Novartis to the top of the drug industry, based on annual sales of about $60 billion.

    Comment?

  13. CVS chooses Amgen's new cholesterol drug over competitorRead the original story

    Nov 23, 2015 | WNFL-AM Green Bay

    U.S. drug benefit manager CVS Health said on Monday it would add Amgen Inc's Repatha cholesterol treatment to its list of covered drugs for private plans over a competing treatment from Regeneron Pharmaceuticals and Sanofi SA. The two competing treatments, which can slash "bad" LDL cholesterol by more than 60 percent, were approved this summer by the U.S. Food and Drug Administration and belong to a new class of medicines called PCSK9 inhibitors.

    Comment?

  14. Why asparagus makes pee smell funny, and other amazing facts about everyday foods and spicesRead the original story w/Photo

    Nov 23, 2015 | Norwalk Citizen News

    Do you know which popular holiday spice can help soothe a toothache? Or why chocolate is toxic to dogs and cats? By digging deep into the molecular chemistry of everyday foods and spices, Cambridge-based chemistry teacher Andy Brunning has the answers. When your doctor says don't eat grapefruit, she means it! Grapefruit contains compounds that can prevent your body from breaking down certain medications, including some statin drugs to lower cholesterol, like Lipitor, and some antihistamines, like Allegra.

    Comment?

  15. Pfizer Given a $36.00 Price Target by Independent Research GmbH AnalystsRead the original story

    Nov 20, 2015 | AmericanBankingNews.com

    The firm presently has a a "neutral" rating on the biopharmaceutical company's stock. Independent Research GmbH's price objective would indicate a potential upside of 11.49% from the stock's current price.

    Comment?

  16. Penn Study: Paying Patients, Doctors Leads to Lower CholesterolRead the original story w/Photo

    Nov 18, 2015 | Phillymag.com

    What's the best way to lower people's cholesterol? Offer financial rewards to both patients and doctors when people take their allotted medications at the appropriate times. That was the main finding from a recently published University of Pennsylvania-led study.

    Comment?

  17. Roche: Small molecule exit will lead to outsourcing opportunitiesRead the original story w/Photo

    Nov 16, 2015 | Drug Researcher

    The Swiss Pharma Giant announced on Friday it was looking to divest four small molecule manufacturing plants which are at the end of their product lifecycle while subsequently investing CHF 300m into a site to make its low volume, more specialised pipeline. The sites are bulk active pharmaceutical ingredient plants in Ireland and the US, and finished formulation facilities in Spain and Italy, and according to Roche spokesperson Claudia Schmitt, the planned exits will create opportunities for contract manufacturing organisations .

    Comment?

  18. People's Pharmacy: Aussie skeptic embraces vicks on soles - Mon, 16 Nov 2015 PSTRead the original story w/Photo

    Nov 16, 2015 | The Spokesman-Review

    Q. I had been coughing for a week with the flu, and I was so tired because it had kept me awake. Besides, the constant cough made my neck sore.

    Comment?

  19. Pfizer Stock Rating Reaffirmed by Piper JaffrayRead the original story

    Nov 15, 2015 | AmericanBankingNews.com

    's stock had its "buy" rating restated by stock analysts at Piper Jaffray in a research report issued to clients and investors on Sunday, Marketbeat.com reports. In other news, major shareholder Pfizer Inc bought 714,285 shares of the stock in a transaction on Tuesday, October 6th.

    Comment?

  20. Heart drugs often unavailable or unaffordableRead the original story

    Nov 13, 2015 | WNFL-AM Green Bay

    Cardiovascular disease drugs are often unavailable or unaffordable in many communities around the world, particularly in poorer countries, a recent study suggests. Four types of medicines are recommended to help prevent deaths from cardiovascular disease: aspirin, beta blockers to control heart rhythm and lower high blood pressure , drugs such as ACE inhibitors to relax blood vessels and improve blood flow and statins to lower cholesterol .

    Comment?